Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 15/20 | 0.79 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.61 |
| ▸ | SHBG | P04278 | 1/20 | 0.61 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HTR1A | P08908 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | AR | P10275 | 1/20 | 0.61 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9404747 | 0.97 | STS (0.78) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL9404855 | 0.93 | STS (0.75) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL3178837 | 0.87 | STS (0.85) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL3178828 | 0.87 | STS (0.85) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL3046316 | 0.87 | STS (0.85) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL3046319 | 0.87 | STS (0.85) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL3051243 | 0.87 | STS (0.84) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL3051244 | 0.87 | STS (0.84) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL13478102 | 0.87 | STS (0.84) | STSSLC22A2NR1I2ABCB11ESR1 | |
| SCHEMBL147038 | 0.87 | STS (0.78) | STSSLC22A2NR1I2ABCB11ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000613-A1 | INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS | FORDOZ PHARMA CORP. (US) | 2026-01-01 | — | — | US | disclosed |
| US-12433841-B2 | Injectable controlled-release formulations of progestogen drugs | FORDOZ PHARMA CORP. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240390289-A1 | Dermal Delivery Device | AGILE THERAPEUTICS, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| CN-115605187-B | Injectable controlled release formulation carrying progestogen drug | 福多兹制药公司 | 2024-09-17 | — | — | CN | disclosed |
| US-12070520-B2 | Dermal delivery device | AGILE THERAPEUTICS, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20230057790-A1 | INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS | FORDOZ PHARMA CORP. (US) | 2023-02-23 | — | — | US | disclosed |
| CN-115605187-A | Injectable controlled release formulation loaded with progestagen drug | 福多兹制药公司（US） | 2023-01-13 | — | — | CN | disclosed |
| CN-109475138-B | Multifunctional structured glycidol/non-glycidol materials | 美国AAK公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-101843603-B | Transdermal delivery of hormones without the need of penetration enhancers | SCHERING AG | 2012-06-27 | — | — | CN | disclosed |
| EP-2410859-A1 | TRANSDERMAL DELIVERY | Agile Therapeutics, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010111488-A1 | TRANSDERMAL DELIVERY | AGILE THERAPEUTICS, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| CN-101843603-A | Transdermal delivery of hormones without the need of penetration enhancers | SCHERING AG | 2010-09-29 | — | — | CN | disclosed |
| CN-1913878-B | Transdermal delivery of hormones without penetration enhancers | SCHERING AG | 2010-05-26 | — | — | CN | disclosed |
| US-20080166413-A1 | Topical pharmaceutical formulations and methods of treatment | PHARMAKODEX LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| CN-1913878-A | Transdermal delivery of hormones without penetration enhancers | SCHERING AG (DE) | 2007-02-14 | — | — | CN | disclosed |
| CN-1287877-C | Electrokinetic delivery device | BIOPHORETIC THERAPEUTIC SYSTEM (US) | 2006-12-06 | — | — | CN | disclosed |
| CN-1437493-A | Electrokinetic delivery device | BIOPHORETIC THERAPEUTIC SYSTEM (US) | 2003-08-20 | — | — | CN | disclosed |
| US-6080735-A | SUITABLE FOR HORMONAL CONTRACEPTION AND CLIMACTERIC HORMONE REPLACEMENT THERAPY (HRT) AS WELL AS FOR TREATMENT OF GYNECOLOGICAL AND ANDROLOGICAL DISEASES | JENAPHARM GMBH & CO. KG (DE) | 2000-06-27 | — | — | US | disclosed |
| CN-1185741-A | Skin permeation enhancer compositions using acyl lactylates | ALZA CORP (US) | 1998-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12070520-B2 | Dermal delivery device | CUTA, KRT18, CD69 | STS 3058/4885SLC22A2 458/4885NR1I2 791/4885 |
| US-20240390289-A1 | Dermal Delivery Device | CUTA, KRT18, CD69 | STS 3058/4885SLC22A2 458/4885NR1I2 791/4885 |
| US-20260000613-A1 | INJECTABLE CONTROLLED-RELEASE FORMULATIONS OF PROGESTOGEN DRUGS | GNRHR, PGR, CYP19A1 | STS 96/4885SLC22A2 2215/4885NR1I2 2601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.